| Year |
Citation |
Score |
| 2024 |
White-Gilbertson S, Lu P, Saatci O, Sahin O, Delaney JR, Ogretmen B, Voelkel-Johnson C. Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidization. The Journal of Biological Chemistry. 107136. PMID 38447798 DOI: 10.1016/j.jbc.2024.107136 |
0.328 |
|
| 2022 |
White-Gilbertson S, Lu P, Esobi I, Echesabal-Chen J, Mulholland PJ, Gooz M, Ogretmen B, Stamatikos A, Voelkel-Johnson C. Polyploid giant cancer cells are dependent on cholesterol for progeny formation through amitotic division. Scientific Reports. 12: 8971. PMID 35624221 DOI: 10.1038/s41598-022-12705-4 |
0.36 |
|
| 2022 |
Bowers RR, Andrade MF, Jones CM, White-Gilbertson S, Voelkel-Johnson C, Delaney JR. Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs). Bmc Cancer. 22: 410. PMID 35421971 DOI: 10.1186/s12885-022-09503-6 |
0.361 |
|
| 2021 |
Lu P, White-Gilbertson S, Beeson G, Beeson C, Ogretmen B, Norris J, Voelkel-Johnson C. Ceramide Synthase 6 Maximizes p53 Function to Prevent Progeny Formation from Polyploid Giant Cancer Cells. Cancers. 13. PMID 34062962 DOI: 10.3390/cancers13092212 |
0.374 |
|
| 2020 |
White-Gilbertson S, Voelkel-Johnson C. Giants and monsters: Unexpected characters in the story of cancer recurrence. Advances in Cancer Research. 148: 201-232. PMID 32723564 DOI: 10.1016/Bs.Acr.2020.03.001 |
0.424 |
|
| 2020 |
Burke B, Eden C, Perez C, Belshoff A, Hart S, Plaza-Rojas L, Delos Reyes M, Prajapati K, Voelkel-Johnson C, Henry E, Gupta G, Guevara-Patiño J. Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction. Frontiers in Oncology. 10: 699. PMID 32500025 DOI: 10.3389/Fonc.2020.00699 |
0.443 |
|
| 2020 |
White-Gilbertson S, Lu P, Jones CM, Chiodini S, Hurley D, Das A, Delaney JR, Norris JS, Voelkel-Johnson C. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis. Cancer Medicine. PMID 32135040 DOI: 10.1002/cam4.2960 |
0.359 |
|
| 2019 |
Goklany S, Lu P, Godeshala S, Hall A, Garrett-Mayer E, Voelkel-Johnson C, Rege K. Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers. Journal of Materials Chemistry. B. PMID 31633707 DOI: 10.1039/C9Tb01286A |
0.503 |
|
| 2019 |
Angel PM, Saunders J, Clift CL, White-Gilbertson S, Voelkel-Johnson C, Yeh E, Mehta A, Drake RR. A Rapid Array-Based Approach to -Glycan Profiling of Cultured Cells. Journal of Proteome Research. PMID 31535553 DOI: 10.1021/Acs.Jproteome.9B00303 |
0.316 |
|
| 2019 |
White-Gilbertson S, Lu P, Norris JS, Voelkel-Johnson C. Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis. Journal of Lipid Research. PMID 30988134 DOI: 10.1194/Jlr.M092247 |
0.45 |
|
| 2019 |
Lu P, White-Gilbertson S, Nganga R, Kester M, Voelkel-Johnson C. Expression of the SNAI2 transcriptional repressor is regulated by C-ceramide. Cancer Biology & Therapy. 1-9. PMID 30836822 DOI: 10.1080/15384047.2019.1579962 |
0.446 |
|
| 2018 |
Nganga R, Oleinik N, Kim J, Panneer Selvam S, De Palma R, Johnson KA, Parikh RY, Gangaraju V, Peterson Y, Dany M, Stahelin RV, Voelkel-Johnson C, Szulc ZM, Bieberich E, Ogretmen B. Receptor-interacting Ser/Thr kinase 1 (RIPK1) and myosin IIA-dependent ceramidosomes form membrane pores that mediate blebbing and necroptosis. The Journal of Biological Chemistry. PMID 30420430 DOI: 10.1074/Jbc.Ra118.005865 |
0.34 |
|
| 2018 |
Johnson BM, Radwan FFY, Hossain A, Doonan BP, Hathaway-Schrader JD, God JM, Voelkel-Johnson CV, Banik NL, Reddy SV, Haque A. Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. Journal of Cellular Biochemistry. PMID 30378157 DOI: 10.1002/Jcb.27913 |
0.334 |
|
| 2018 |
Lewis CS, Voelkel-Johnson C, Smith CD. Targeting Sphingosine Kinases for the Treatment of Cancer. Advances in Cancer Research. 140: 295-325. PMID 30060814 DOI: 10.1016/Bs.Acr.2018.04.015 |
0.339 |
|
| 2018 |
Voelkel-Johnson C, Norris JS, White-Gilbertson S. Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. Advances in Cancer Research. 140: 265-293. PMID 30060812 DOI: 10.1016/Bs.Acr.2018.04.014 |
0.437 |
|
| 2018 |
Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, Voelkel-Johnson C. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunology, Immunotherapy : Cii. PMID 29396710 DOI: 10.1007/S00262-018-2120-5 |
0.427 |
|
| 2018 |
Helke K, Angel P, Lu P, Garrett-Mayer E, Ogretmen B, Drake R, Voelkel-Johnson C. Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Scientific Reports. 8: 1627. PMID 29374263 DOI: 10.1038/S41598-018-20102-Z |
0.313 |
|
| 2017 |
Scheffel MJ, Helke K, Lu P, Bowers JS, Ogretmen B, Garrett-Mayer E, Paulos CM, Voelkel-Johnson C. Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. Scientific Reports. 7: 15552. PMID 29138469 DOI: 10.1038/S41598-017-15791-X |
0.348 |
|
| 2017 |
Camp ER, Patterson LD, Kester M, Voelkel-Johnson C. Therapeutic Implications Of Bioactive Sphingolipids: A Focus On Colorectal Cancer. Cancer Biology & Therapy. 0. PMID 28686076 DOI: 10.1080/15384047.2017.1345396 |
0.388 |
|
| 2017 |
Sambandam Y, Reddy SV, Mulligan JL, Voelkel-Johnson C, Wagner CL. Vitamin D Modulation of TRAIL Expression in Human Milk and Mammary Epithelial Cells. Scientific Reports. 7: 4362. PMID 28659589 DOI: 10.1038/S41598-017-04521-Y |
0.307 |
|
| 2016 |
Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, Voelkel-Johnson C. Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. Cancer Research. 76: 6006-6016. PMID 27742673 DOI: 10.1158/0008-5472.Can-16-0587 |
0.416 |
|
| 2016 |
Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget. PMID 27517489 DOI: 10.18632/Oncotarget.11112 |
0.469 |
|
| 2015 |
Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Molecular Cancer Therapeutics. PMID 26494858 DOI: 10.1158/1535-7163.Mct-15-0279 |
0.442 |
|
| 2015 |
Tirodkar TS, Lu P, Bai A, Scheffel MJ, Gencer S, Garrett-Mayer E, Bielawska A, Ogretmen B, Voelkel-Johnson C. Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner. The Journal of Biological Chemistry. 290: 13157-67. PMID 25839235 DOI: 10.1074/Jbc.M114.631325 |
0.663 |
|
| 2015 |
Sundaram K, Sambandam Y, Balasubramanian S, Pillai B, Voelkel-Johnson C, Ries WL, Reddy SV. STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells. Bone. 71: 137-44. PMID 25445452 DOI: 10.1016/J.Bone.2014.10.016 |
0.446 |
|
| 2014 |
Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga OS, Simms P, Beeson G, Voelkel-Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S. Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Research. 74: 6036-47. PMID 25164014 DOI: 10.1158/0008-5472.Can-14-1084 |
0.4 |
|
| 2014 |
Dai L, Plaisance-Bonstaff K, Voelkel-Johnson C, Smith CD, Ogretmen B, Qin Z, Parsons C. Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells. Plos One. 9: e102314. PMID 25010828 DOI: 10.1371/Journal.Pone.0102314 |
0.422 |
|
| 2014 |
Gosnell H, Kasman LM, Potta T, Vu L, Garrett-Mayer E, Rege K, Voelkel-Johnson C. Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 176: 35-43. PMID 24370892 DOI: 10.1016/J.Jconrel.2013.12.012 |
0.345 |
|
| 2014 |
Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, Voelkel-Johnson C, Smith CD, Ogretmen B, Parsons C. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Molecular Cancer Therapeutics. 13: 154-64. PMID 24140934 DOI: 10.1158/1535-7163.Mct-13-0466 |
0.491 |
|
| 2013 |
Kasman L, Voelkel-Johnson C. An orthotopic bladder cancer model for gene delivery studies. Journal of Visualized Experiments : Jove. 50181. PMID 24326612 DOI: 10.3791/50181 |
0.368 |
|
| 2013 |
May LA, Kramarenko II, Brandon CS, Voelkel-Johnson C, Roy S, Truong K, Francis SP, Monzack EL, Lee FS, Cunningham LL. Inner ear supporting cells protect hair cells by secreting HSP70. The Journal of Clinical Investigation. 123: 3577-87. PMID 23863716 DOI: 10.1172/Jci68480 |
0.365 |
|
| 2013 |
Qin Z, Dai L, Plaisance-Bonstaff K, Senkal C, Wang W, Reske TM, Del Valle L, Voelkel-Johnson C, Flemington E, Ogretmen B, Smith CD, Parsons C. Targeting Sphingosine Kinase Induces Apoptosis and Regression Of Virus-Associated Lymphoma In Vivo Blood. 122: 4414-4414. DOI: 10.1182/Blood.V122.21.4414.4414 |
0.467 |
|
| 2012 |
Tirodkar TS, Voelkel-Johnson C. Sphingolipids in apoptosis. Experimental Oncology. 34: 231-42. PMID 23070008 |
0.686 |
|
| 2012 |
Brandon CS, Voelkel-Johnson C, May LA, Cunningham LL. Dissection of adult mouse utricle and adenovirus-mediated supporting-cell infection. Journal of Visualized Experiments : Jove. PMID 22491073 DOI: 10.3791/3734 |
0.372 |
|
| 2012 |
Kasman L, Onicescu G, Voelkel-Johnson C. Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells. Prostate Cancer. 2012: 137163. PMID 22288017 DOI: 10.1155/2012/137163 |
0.478 |
|
| 2011 |
Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nature Reviews. Urology. 8: 417-27. PMID 21670755 DOI: 10.1038/Nrurol.2011.81 |
0.509 |
|
| 2011 |
Murali A, Kasman L, Voelkel-Johnson C. Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer. Bmc Cancer. 11: 168. PMID 21569442 DOI: 10.1186/1471-2407-11-168 |
0.45 |
|
| 2010 |
Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular Cancer Therapeutics. 9: 2220-31. PMID 20682655 DOI: 10.1158/1535-7163.Mct-10-0274 |
0.315 |
|
| 2010 |
Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Research. 70: 6313-24. PMID 20631069 DOI: 10.1158/0008-5472.Can-10-0999 |
0.384 |
|
| 2010 |
Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Molecular Cancer Therapeutics. 9: 1378-95. PMID 20442308 DOI: 10.1158/1535-7163.Mct-09-1131 |
0.404 |
|
| 2009 |
Kasman LM, Barua S, Lu P, Rege K, Voelkel-Johnson C. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Molecular Pharmaceutics. 6: 1612-9. PMID 19655763 DOI: 10.1021/Mp9000958 |
0.382 |
|
| 2009 |
Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Research. 69: 6282-9. PMID 19638595 DOI: 10.1158/0008-5472.Can-09-1176 |
0.492 |
|
| 2009 |
White-Gilbertson SJ, Kasman L, McKillop J, Tirodkar T, Lu P, Voelkel-Johnson C. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. The Journal of Urology. 182: 1178-85. PMID 19625063 DOI: 10.1016/J.Juro.2009.05.005 |
0.692 |
|
| 2009 |
White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. Molecular Oncology. 3: 402-8. PMID 19546037 DOI: 10.1016/J.Molonc.2009.05.003 |
0.416 |
|
| 2009 |
Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Molecular Pharmacology. 76: 342-55. PMID 19483104 DOI: 10.1124/Mol.109.056523 |
0.447 |
|
| 2009 |
Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Molecular Cancer Therapeutics. 8: 1280-91. PMID 19417161 DOI: 10.1158/1535-7163.Mct-09-0073 |
0.423 |
|
| 2009 |
White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L, Voelkel-Johnson C. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells Oncogene. 28: 1132-1141. PMID 19137010 DOI: 10.1038/Onc.2008.468 |
0.552 |
|
| 2009 |
Voelkel-Johnson C. Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer Biology & Therapy. 8: 81-3. PMID 19127121 DOI: 10.4161/Cbt.8.1.7519 |
0.46 |
|
| 2008 |
White-Gilbertson S, Rubinchik S, Voelkel-Johnson C. Transformation, translation and TRAIL: an unexpected intersection. Cytokine & Growth Factor Reviews. 19: 167-72. PMID 18353705 DOI: 10.1016/J.Cytogfr.2008.01.007 |
0.497 |
|
| 2007 |
White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, Voelkel-Johnson C. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radical Biology & Medicine. 43: 1313-21. PMID 17893044 DOI: 10.1016/J.Freeradbiomed.2007.06.015 |
0.484 |
|
| 2006 |
White SJ, Voelkel-Johnson C. Illuminating TRAIL gene therapy. Cancer Biology & Therapy. 5: 1521-2. PMID 17204862 DOI: 10.4161/Cbt.5.11.3691 |
0.517 |
|
| 2006 |
Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Therapy. 14: 327-34. PMID 17186014 DOI: 10.1038/Sj.Cgt.7701017 |
0.464 |
|
| 2006 |
White SJ, Lu P, Keller GM, Voelkel-Johnson C. Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biology & Therapy. 5: 1618-23. PMID 17106251 DOI: 10.4161/Cbt.5.12.3352 |
0.545 |
|
| 2006 |
Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S, Dong JY, McKillop J, Norris K, Obeid L, Rubinchik S, ... ... Voelkel-Johnson C, et al. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Therapy. 13: 1045-51. PMID 16763610 DOI: 10.1038/Sj.Cgt.7700965 |
0.411 |
|
| 2006 |
El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Therapy. 13: 281-9. PMID 16167063 DOI: 10.1038/Sj.Cgt.7700905 |
0.523 |
|
| 2005 |
Voelkel-Johnson C, Hannun YA, El-Zawahry A. Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. Molecular Cancer Therapeutics. 4: 1320-7. PMID 16170023 DOI: 10.1158/1535-7163.Mct-05-0086 |
0.553 |
|
| 2005 |
El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. Bmc Cancer. 5: 2. PMID 15638938 DOI: 10.1186/1471-2407-5-2 |
0.485 |
|
| 2005 |
Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Therapy. 12: 12-8. PMID 15514684 DOI: 10.1038/Sj.Cgt.7700746 |
0.538 |
|
| 2005 |
El-Zawahry AM, Voelkel-Johnson C. 324. TRAIL Gene Therapy Is a Promising Therapy for Bladder Cancer Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.327 |
0.555 |
|
| 2003 |
Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Therapy. 10: 814-22. PMID 14605667 DOI: 10.1038/Sj.Cgt.7700651 |
0.48 |
|
| 2003 |
Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biology & Therapy. 2: 283-90. PMID 12878867 DOI: 10.4161/Cbt.2.3.398 |
0.49 |
|
| 2002 |
Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biology & Therapy. 1: 520-7. PMID 12496481 DOI: 10.4161/Cbt.1.5.169 |
0.546 |
|
| 2002 |
Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Therapy. 9: 164-72. PMID 11857034 DOI: 10.1038/Sj.Cgt.7700420 |
0.471 |
|
| 2000 |
Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 348-58. PMID 11020350 DOI: 10.1006/Mthe.2000.0139 |
0.521 |
|
| 2000 |
Voelkel-Johnson C, Voeks DJ, Greenberg NM, Barrios R, Maggouta F, Kurtz DT, Schwartz DA, Keller GM, Papenbrock T, Clawson GA, Norris JS. Genomic instability-based transgenic models of prostate cancer Carcinogenesis. 21: 1623-1627. DOI: 10.1093/Carcin/21.5.623 |
0.312 |
|
| 1996 |
Thorne TE, Voelkel-Johnson C, Casey WM, Parks LW, Laster SM. The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor. Journal of Virology. 70: 8502-7. PMID 8970973 DOI: 10.1128/jvi.70.12.8502-8507.1996 |
0.344 |
|
| Show low-probability matches. |